Infectious Disease Diagnostic Testing: World Market Analysis, 2024-2029
상품코드:1550802
리서치사:Kalorama Information
발행일:2024년 11월
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
한글목차
이 보고서는 세계의 감염병 진단 검사 시장에 대해 조사했으며, 시장 개요와 함께 2024-2029년까지의 예측, 지역별 동향, 시장 진출기업 프로파일 등을 정리하여 전해드립니다.
목차
제1장 주요 요약
제2장 시장 환경
개요
인구
연령 분포
거시경제 환경
세계 경제 전망
1인당 국내총생산
세계의 헬스케어 동향
감염증 사례
의료 제공업체
환자 활동
제3장 감염증 IVD 제품과 시장
제4장 세계 시장
개요
북미
미국
캐나다
멕시코
서유럽
독일
프랑스
영국
이탈리아
스페인
기타 서유럽
아시아태평양
중국
일본
인도
한국
기타 아시아태평양
기타 지역
아프리카/중동
중남미
동유럽
제5장 기업 개요
Abbott Laboratories
Becton Dickinson and Company
Bio-Rad Laboratories
bioMerieux
BIOFIRE Diagnostics Business
Bruker Corporation
Danaher Corporation
DiaSorin
Grifols S.A.
Hologic
PANTHER Molecular System
QIAGEN
QuidelOrtho Corporation
Solana Business
Roche Holding
Siemens Healthineers
Thermo Fisher Scientific
LSH
영문 목차
영문목차
Stay Ahead of the Curve with "Infectious Disease Diagnostic Testing: World Market Analysis, 2024-2029": With the global demand for infectious disease IVD products projected to surge, understanding market trends is crucial for healthcare providers, investors, and industry stakeholders. This report offers a detailed analysis of the factors driving growth, including the increasing recognition of infectious diseases as a global health concern.
As infectious diseases continue to pose significant global health challenges, diagnostic testing has emerged as a vital tool in detecting and managing these threats. Today, infectious disease testing stands at the forefront of the rapidly expanding in vitro diagnostics (IVD) industry, representing one of its largest and most dynamic segments.
This comprehensive market research report from Kalorama Information delves into the world of infectious disease IVD, presenting unparalleled insights and forecasts for 2024-2029. Designed for industry professionals, investors, and market strategists, this report will equip you with the knowledge needed to stay ahead in a competitive and rapidly evolving sector.
Report Features:
Comprehensive Market Coverage: Understand the dynamic landscape of infectious disease diagnostics, spanning key test categories such as:
Healthcare-Associated Infections (HAIs)
COVID-19
Hepatitis
STIs
Influenza
HIV/AIDS
Tuberculosis
TORCH
Other infectious diseases (including Dengue Fever, Emerging Infections, Fungal, Lyme Disease, Malaria, Other Parasitic, RSV, Streptococcal)
Global Reach with Local Insights: Gain valuable perspectives on opportunities in diverse geographic regions, including North America, Western Europe, Asia/Pacific, and emerging markets across Central & South America, Africa, and the Middle East.
Strategic Market Drivers: Explore the macroeconomic and healthcare trends driving the need for advanced diagnostics and how aging populations and globalized threats are influencing market growth.
Competitive Intelligence: Analyze the leading players and their IVD innovations, helping you benchmark against industry leaders and identify potential partnerships or competitive advantages.
Scope and Methodology You Can Trust: Backed by Kalorama Information's extensive experience and robust analytical frameworks, this report synthesizes data from public records, epidemiological research, key competitor analysis, and economic modeling. Our insights are further enriched by expert interviews and proprietary databases, ensuring you get actionable, reliable forecasts.
Table of Contents
Chapter 1: Executive Summary
A Mix of Traditional and Emerging Testing Technologies
Market Drivers
The World Infectious Disease Testing Market
Table 1-1: World Infectious Disease Diagnostic Test Market, 2024-2029 ($ million)
Figure 1-1: World Infectious Disease Diagnostic Test Market, 2024-2029 ($ million)
Table 2-1: Population by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
Figure 2-1: Global Population, by Region, 2023 vs. 2029 (million) (Asia/Pacific; North America; Western Europe; Other Regions)
Age Distribution
Table 2-2: Population 50 Years & Older by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
Table 2-3: Population 65 Years & Older by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
Macroeconomic Environment
Global Economic Outlook
Table 2-4: Gross Domestic Product by Country, 2023-2029 ($ billion) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
Per Capita Gross Domestic Product
Table 2-5: Per Capita Gross Domestic Product by Country, 2023-2029 (dollars) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
Global Healthcare Trends
Infectious Disease Cases
Table 2-6: Number of Infectious Disease Cases by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
Figure 2-2: Number of Global Infectious Disease Cases, by Region, 2023 vs. 2029 (million) (Asia/Pacific; North America; Western Europe; Other Regions)
Medical Providers
Table 2-7: Medical Providers, Selected Countries, 2021 (Africa/M.E.; Canada; Central/South America; China; Eastern Europe; France; Germany; India; Italy; Japan; Mexico; Other Asia/Pacific; Other Western Europe; South Korea; Spain; United States)
Patient Activity
Hospital Admissions
Table 2-8: Hospital Admissions by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
Inpatient Days
Table 2-9: Inpatient Days by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
Outpatient Consultations
Table 2-10: Outpatient Consultations by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
IVD Tests
Table 2-11: IVD Tests by Country, 2023-2029 (million) (Asia/Pacific [China, India, Japan, South Korea, Other]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
Figure 2-3: In Vitro Diagnostic (IVD) Tests, by Region, 2023 vs. 2029 (million) (Asia/Pacific; North America; Western Europe; Other Regions)
Table 4-1: Infectious Disease IVD Products Demand, by Country, 2024-2029 ($ million) (Asia/Pacific [China, India, Japan, South Korea, Other APAC]; North America [Canada, Mexico, United States]; Western Europe [France, Germany, Italy, Spain, United Kingdom, Other Western Europe]; Other Regions [Africa/Middle East, Central & South America, Eastern Europe])
North America
Table 4-2: North America: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
United States
Table 4-3: United States: Infectious Disease IVD Products Demand, by Type, 2024-2029 ($ million) (COVID-19; HAIs; Hepatitis; HIV/AIDS; Influenza; STIs; TORCH; Tuberculosis; Other Infections)
